1 |
Paisan-Ruiz C, Jain S, Evans EW et al (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600
DOI
ScienceOn
|
2 |
Zimprich A, Biskup S, Leitner P et al (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607
DOI
ScienceOn
|
3 |
Bialik S and Kimchi A (2010) Lethal weapons: DAP-kinase, autophagy and cell death: DAP-kinase regulates autophagy. Curr Opin Cell Biol 22, 199-205
DOI
ScienceOn
|
4 |
Kuo JC, Wang WJ, Yao CC, Wu PR and Chen RH (2006) The tumor suppressor DAPK inhibits cell motility by blocking the integrin-mediated polarity pathway. J Cell Biol 172, 619-631
DOI
ScienceOn
|
5 |
Wang LH, Besirli CG and Johnson EM Jr (2004) Mixedlineage kinases: a target for the prevention of neurodegeneration. Annu Rev Pharmacol Toxicol 44, 451-474
DOI
ScienceOn
|
6 |
Chuang YT, Fang LW, Lin-Feng MH, Chen RH and Lai MZ (2008) The tumor suppressor death-associated protein kinase targets to TCR-stimulated NF-kappa B activation. J Immunol 180, 3238-3249
DOI
|
7 |
Chuang YT, Lin YC, Lin KH et al (2011) Tumor suppressor death-associated protein kinase is required for full IL-1beta production. Blood 117, 960-970
DOI
ScienceOn
|
8 |
Bialik S and Kimchi A (2006) The death-associated protein kinases: structure, function, and beyond. Annu Rev Biochem 75, 189-210
DOI
ScienceOn
|
9 |
Ferrer I, Blanco R, Carmona M et al (2001) Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies. J Neural Transm 108, 1383-1396
DOI
ScienceOn
|
10 |
Parkinson Study G (2004) The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD. Neurology 62, 330-332
DOI
ScienceOn
|
11 |
Zhang D, Lin J and Han J (2010) Receptor-interacting protein (RIP) kinase family. Cell Mol Immunol 7, 243-249
DOI
ScienceOn
|
12 |
Meylan E and Tschopp J (2005) The RIP kinases: crucial integrators of cellular stress. Trends Biochem Sci 30, 151-159
DOI
ScienceOn
|
13 |
Dzamko N, Inesta-Vaquera F, Zhang J et al (2012) The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. PLoS One 7, e39132
DOI
|
14 |
Gardet A, Benita Y, Li C et al (2010) LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol 185, 5577-5585
DOI
|
15 |
Tong Y, Yamaguchi H, Giaime E et al (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A 107, 9879-9884
DOI
ScienceOn
|
16 |
Tong Y, Giaime E, Yamaguchi H et al (2012) Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol Neurodegener 7, 2
DOI
ScienceOn
|
17 |
Lee S, Liu HP, Lin WY, Guo H and Lu B (2010) LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction. J Neurosci 30, 16959-16969
DOI
ScienceOn
|
18 |
Parisiadou L, Yu J, Sgobio C et al (2014) LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity. Nat Neurosci 17, 367-376
DOI
ScienceOn
|
19 |
Herzig MC, Kolly C, Persohn E et al (2011) LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet 20, 4209-4223
DOI
ScienceOn
|
20 |
Thevenet J, Pescini Gobert R, Hooft van Huijsduijnen R, Wiessner C and Sagot YJ (2011) Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS One 6, e21519
DOI
|
21 |
Hakimi M, Selvanantham T, Swinton E et al (2011) Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm 118, 795-808
DOI
ScienceOn
|
22 |
Funayama M, Hasegawa K, Ohta E et al (2005) An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 57, 918-921
DOI
ScienceOn
|
23 |
Alegre-Abarrategui J, Christian H, Lufino MM et al (2009) LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet 18, 4022-4034
DOI
ScienceOn
|
24 |
Liu Z, Wang X, Yu Y et al (2008) A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A 105, 2693-2698
DOI
ScienceOn
|
25 |
Matta S, Van Kolen K, da Cunha R et al (2012) LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron 75, 1008-1021
DOI
ScienceOn
|
26 |
Tong Y, Pisani A, Martella G et al (2009) R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci U S A 106, 14622-14627
DOI
ScienceOn
|
27 |
Chen CY, Weng YH, Chien KY et al (2012) (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. Cell Death Differ 19, 1623-1633
DOI
ScienceOn
|
28 |
Martin I, Kim JW, Lee BD et al (2014) Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease. Cell 157, 472-485
DOI
ScienceOn
|
29 |
MacLeod D, Dowman J, Hammond R, Leete T, Inoue K and Abeliovich A (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52, 587-593
DOI
ScienceOn
|
30 |
Hockey LN, Kilpatrick BS, Eden ER et al (2015) Dysregulation of lysosomal morphology by pathogenic LRRK2 is corrected by TPC2 inhibition. J Cell Sci 128, 232-238
DOI
ScienceOn
|
31 |
Dodson MW, Zhang T, Jiang C, Chen S and Guo M (2012) Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum Mol Genet 21, 1350-1363
DOI
|
32 |
Kim S, Seo JH and Suh YH (2004) Alpha-synuclein, Parkinson's disease, and Alzheimer's disease. Parkinsonism Relat Disord 10 Suppl 1, S9-13
DOI
ScienceOn
|
33 |
Sanchez-Danes A, Richaud-Patin Y, Carballo-Carbajal I et al (2012) Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol Med 4, 380-395
DOI
|
34 |
Koehler NK, Stransky E, Shing M et al (2013) Altered serum IgG levels to alpha-synuclein in dementia with Lewy bodies and Alzheimer's disease. PLoS One 8, e64649
DOI
|
35 |
Guo JL, Covell DJ, Daniels JP et al (2013) Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell 154, 103-117
DOI
ScienceOn
|
36 |
Culvenor JG, McLean CA, Cutt S et al (1999) Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. Am J Pathol 155, 1173-1181
DOI
ScienceOn
|
37 |
Linnertz C, Lutz MW, Ervin JF et al (2014) The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease. Hum Mol Genet 23, 4814-4821
DOI
ScienceOn
|
38 |
Lin X, Parisiadou L, Gu XL et al (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 64, 807-827
DOI
ScienceOn
|
39 |
Kawakami F, Yabata T, Ohta E et al (2012) LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS One 7, e30834
DOI
|
40 |
Li Y, Liu W, Oo TF et al (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 12, 826-828
DOI
ScienceOn
|
41 |
Franchi L, Warner N, Viani K and Nunez G (2009) Function of Nod-like receptors in microbial recognition and host defense. Immunol Rev 227, 106-128
DOI
ScienceOn
|
42 |
Moskvina V, Harold D, Russo G et al (2013) Analysis of genome-wide association studies of Alzheimer disease and of Parkinson disease to determine if these 2 diseases share a common genetic risk. JAMA Neurol 70, 1268-1276
|
43 |
Fuss IJ, Neurath M, Boirivant M et al (1996) Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157, 1261-1270
|
44 |
Barrett JC, Hansoul S, Nicolae DL et al (2008) Genomewide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 40, 955-962
DOI
ScienceOn
|
45 |
Zhang FR, Huang W, Chen SM et al (2009) Genomewide association study of leprosy. N Engl J Med 361, 2609-2618
DOI
ScienceOn
|
46 |
Xavier RJ and Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448, 427-434
DOI
ScienceOn
|
47 |
Niessner M and Volk BA (1995) Altered Th1/Th2 cytokine profiles in the ntestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 101, 428-435
DOI
|
48 |
Liu Z, Lee J, Krummey S, Lu W, Cai H and Lenardo MJ (2011) The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat Immunol 12, 1063-1070
DOI
ScienceOn
|
49 |
Krutzik SR, Ochoa MT, Sieling PA et al (2003) Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat Med 9, 525-532
DOI
ScienceOn
|
50 |
Devine MJ, Plun-Favreau H and Wood NW (2011) Parkinson's disease and cancer: two wars, one front. Nat Rev Cancer 11, 812-823
DOI
ScienceOn
|
51 |
Looyenga BD, Furge KA, Dykema KJ et al (2011) Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proc Natl Acad Sci U S A 108, 1439-1444
DOI
ScienceOn
|
52 |
Agalliu I, San Luciano M, Mirelman A et al (2015) Higher Frequency of Certain Cancers in LRRK2 G2019S Mutation Carriers With Parkinson Disease: A Pooled Analysis. JAMA Neurol 72, 58-65
DOI
ScienceOn
|
53 |
Inzelberg R, Cohen OS, Aharon-Peretz J et al (2012) The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. Neurology 78, 781-786
DOI
|
54 |
Saunders-Pullman R, Barrett MJ, Stanley KM et al (2010) LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease. Mov Disord 25, 2536-2541
DOI
ScienceOn
|
55 |
Kuo JC, Lin JR, Staddon JM, Hosoya H and Chen RH (2003) Uncoordinated regulation of stress fibers and focal adhesions by DAP kinase. J Cell Sci 116, 4777-4790
DOI
ScienceOn
|
56 |
Gingras AC, Raught B and Sonenberg N (1999) eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 68, 913-963
DOI
ScienceOn
|
57 |
Gehrke S, Imai Y, Sokol N and Lu B (2010) Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466, 637-641
DOI
ScienceOn
|